Glimepiride Metformin  Tablet in pharma franchise in Meghalaya

Glimepiride Metformin in PCD pharma franchise in Thiruvananthapuram

Glimepiride Metformin in top pharma company in Bhubaneswar

Glimepiride Metformin in pcd pharma supplier in Patna

Glimepiride Metformin in phama franchise company in india
Glimepiride Metformin in phama franchise company in Hyderabad

Gimtype M2 Forte Tablet

Composition : Glimepiride (2mg) + Metformin (1000mg) SR Bilayered Smart Tablet

Dosage Form : Tablet

Packaging Type : Blister

Packaging : 10*10

Price : ₹1/-

Please Contact For Best Price

Gimtype M2 Forte is a bilayered smart tablet specifically designed for the effective management of type 2 diabetes mellitus. This innovative formulation combines two key active ingredients: Glimepiride (2 mg) and Metformin (1000 mg) sustained release (SR). Together, these components provide a comprehensive approach to controlling blood glucose levels, making it an essential option for patients with diabetes.

Glimepiride, a member of the sulfonylurea class, functions by stimulating the pancreas to release insulin, which is vital for lowering blood sugar levels. This action helps to improve glycemic control, particularly after meals. Metformin, on the other hand, is a biguanide that enhances insulin sensitivity in peripheral tissues and decreases hepatic glucose production. The sustained release formulation of Metformin ensures a gradual release of the medication, which helps maintain stable blood glucose levels throughout the day while minimizing gastrointestinal side effects.

The combination of Glimepiride and Metformin in Gimtype M2 Forte not only aids in achieving better glycemic control but also helps reduce the risk of diabetes-related complications. This dual-action approach is particularly beneficial for patients who may not achieve adequate control with Metformin alone. By addressing multiple pathways involved in glucose regulation, Gimtype M2 Forte provides a more effective solution for managing type 2 diabetes..

Read More

About the Product

Gimtype M2 Forte is a bilayered smart tablet specifically designed for the effective management of type 2 diabetes mellitus. This innovative formulation combines two key active ingredients: Glimepiride (2 mg) and Metformin (1000 mg) sustained release (SR). Together, these components provide a comprehensive approach to controlling blood glucose levels, making it an essential option for patients with diabetes.

Glimepiride, a member of the sulfonylurea class, functions by stimulating the pancreas to release insulin, which is vital for lowering blood sugar levels. This action helps to improve glycemic control, particularly after meals. Metformin, on the other hand, is a biguanide that enhances insulin sensitivity in peripheral tissues and decreases hepatic glucose production. The sustained release formulation of Metformin ensures a gradual release of the medication, which helps maintain stable blood glucose levels throughout the day while minimizing gastrointestinal side effects.

The combination of Glimepiride and Metformin in Gimtype M2 Forte not only aids in achieving better glycemic control but also helps reduce the risk of diabetes-related complications. This dual-action approach is particularly beneficial for patients who may not achieve adequate control with Metformin alone. By addressing multiple pathways involved in glucose regulation, Gimtype M2 Forte provides a more effective solution for managing type 2 diabetes..

Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Hypoglycemia can also occur, especially if meals are missed or if there is increased physical activity.

Gimtype M2 Forte is indicated for the management of type 2 diabetes mellitus, particularly in conjunction with diet and exercise.

Consult your healthcare provider before starting this medication, especially if you have a history of kidney or liver disease.

Store Gimtype M2 Forte tablets in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Get in Touch